REHOVOT, Israel and BRIDGEWATER, N.J., Feb. 26, 2015 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq:FOMX), ("Foamix Pharmaceuticals"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced today that David Domzalski, President of Foamix Pharmaceuticals, will provide a corporate overview and business update at the Cowen & Company 35 th Annual Health Care Conference.

Presentation Details:
Title: Cowen & Company 35th Annual Health Care Conference
Date:  Monday, March 2, 2015
Time:  3:30pm Eastern
Location:  The Boston Marriott Copley Place, Boston, MA
Webcast:  http://wsw.com/webcast/cowen22/fomx

About Foamix Pharmaceuticals

We are a clinical-stage specialty pharmaceutical company focused on developing and commercializing our proprietary minocycline foam for the treatment of acne and other skin conditions. Our lead product candidate, FMX101 for moderate-to-severe acne is a topical foam formulation of the antibiotic minocycline. We also have early-stage stable foam formulations of various drugs for the treatment of common dermatological indications.
CONTACT: U.S. Investor Relations         Andrew McDonald         LifeSci Advisors, LLC         646-597-6987         andrew@lifesciadvisors.com

Foamix, Ltd. logo